Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders

US10925876B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Raphaelle Berger · New York, US
• Guizhen Dong
• Subharekha Raghavan · Teaneck, US
• Zhiqiang Yang · Westfield, US

Key dates

• Filing date: May 12, 2017
• Grant date: Feb 23, 2021
• Expiry date: May 12, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R1, R2, R3, R4, and R5 are as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy.